Trademark: 79321550
Word
FIBROBODY
Status Date
Tuesday, January 25, 2022
Registration Number
6624524
Registration Date
Tuesday, January 25, 2022
Filing Date
Thursday, February 18, 2021
Published for Opposition
Tuesday, November 9, 2021
5 Pharmaceutical preparations for the treatment of fibrotic disease, liver- kidney- and lung fibrosis, inflammatory conditions with a proven fibrotic disease component and inflammatory bowel disease; drug delivery agents in the form of parenteral formulations and per-oral formulations, tablets and capsules that facilitate the delivery of pharmaceutical preparations; pharmaceutical drugs for the treatment of fibrotic disease, liver- kidney- and lung fibrosis, inflammatory conditions with a proven fibrotic disease component and inflammatory bowel disease; drug delivery agents in the form of parenteral formulations and per-oral formulations, tablets and capsules that facilitate the delivery of pharmaceutical preparations; biochemical medicines for the treatment of fibrotic disease, liver- kidney- and lung fibrosis, inflammatory conditions with a proven fibrotic disease component and inflammatory bowel disease; chemical preparations for pharmaceutical purposes, namely, for the treatment of fibrotic disease, liver- kidney- and lung fibrosis, inflammatory conditions with a proven fibrotic disease component and inflammatory bowel disease; diagnostic agents for pharmaceutical purposes; pharmaceutical substances and preparations for the treatment of fibrotic disease, liver- kidney- and lung fibrosis, inflammatory conditions with a proven fibrotic disease component and inflammatory bowel disease; drug delivery agents consisting of compounds that facilitate delivery of pharmaceutical preparations
1 Chemical additives for use in the manufacture of pharmaceuticals; chemical preparations for use in the manufacture of pharmaceuticals; active chemical ingredients for use in the manufacture of pharmaceuticals for treating fibrotic disease, liver- kidney- and lung fibrosis, inflammatory conditions with a proven fibrotic disease component and inflammatory bowel disease
44 Medical services, namely, in vitro analysis for medical and pharmaceutical use; medical services, namely, in vitro testing for medical and pharmaceutical use; consultancy and information services provided via the internet relating to pharmaceutical products
42 Pharmaceutical research services; conducting clinical trials for others relating to pharmaceuticals; pharmaceutical research and development; pharmaceutical product evaluation; consultancy relating to pharmaceutical research and development; laboratory research services relating to pharmaceuticals; providing information about the results of clinical trials for pharmaceuticals; providing information about medical and scientific research in the field of pharmaceuticals; scientific research services in the field of proteins, antibodies, microorganisms and cells; research and development services in the field of antibody technology; design and development of medical technology
Sep 30, 2021
Sn Assigned For Sect 66a Appl From Ib
Oct 4, 2021
Limitation From Original Application Entered
Oct 6, 2021
New Application Office Supplied Data Entered
Oct 6, 2021
Assigned To Examiner
Oct 6, 2021
Approved For Pub - Principal Register
Oct 12, 2021
Application Filing Receipt Mailed
Oct 20, 2021
Notice Of Publication
Nov 9, 2021
Published For Opposition
Jan 25, 2022
Registered-Principal Register
Feb 24, 2022
Grant Of Protection Created, To Be Sent To Ib
May 18, 2022
Final Disposition Processed
May 19, 2022
Final Disposition Notice Sent To Ib
Jun 5, 2022
Notification Processed By Ib
Sep 20, 2024
Change Of Name/Address Rec'd From Ib
Trademark Alertz updated from USPTO on 2030-01-24
